Bio-Path Holdings (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize(R) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, has closed a public offering of 1,710,600 shares of common stock. Bio-Path Holdings secured approximately $13 million in gross proceeds, with each of the shares sold at the public offering price of $7.60. Bio-Path intends to use the proceeds for working capital and general corporate purposes. ROTH Capital Partners acted as sole placement agent for the offering.
For more information about the company, visit www.BioPathHoldings.com
About Bio-Path Holdings Inc.
Bio-Path Holdings is a biotechnology company developing DNAbilize(R), a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous infusion. Bio-Path’s lead product candidate, prexigebersen (“BP1001,” targeting the Grb2 protein), is in a Phase 2 study for blood cancers and prexigebersen-A, a drug product modification of prexigebersen, is under consideration by the FDA to commence Phase 1 studies in solid tumors. This is followed by “BP1002,” targeting the Bcl-2 protein, where it is being evaluated in lymphoma clinical studies.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.